Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tagrisso (osimertinib) For the Treatment of EGFR mutation in Non-Small Cell Lung Cancer

Drug(Brand/Generic)

Tagrisso (osimertinib)

Therapy Class

EGFR tyrosine kinase inhibitor

Current Indication

Non-small cell lung cancer

Market Sector

Oncology

Development Status

Approved in US and Europe

Developer

AstraZeneca
Expand

Go Top